The following letter was not responded by Bilha Fischer, Professor at Bar-Ilan University:
Dear Mrs. Fischer,
my name is Alexander Cherkasky, I am inventor and biologist and I am writing to you, because I ask your substabtiated statement about my following findings: your and Daniel Offen's international patent application WO2016147185 for adenosine thiophosphate derivates and uses thereof "is capable of disintegrating, or disintegrates complexes of amyloid beta with zinc" (your description) and thus could be used "in the treatment of a neurodegenerative disease or disorder" (your claim 21) and for the treatment of Alzheimer's disesase (your claim 22). Possible therapeutic applications are listed in your description and include not only Alzheimer's disesases, but also prion disease and Huntington's Disease.
This your and Offen's publication is not new and not inventive because of my prior German patent document DE19953696 claiming priority and novelty worldwide. My invention comprises every small mollecule which cleaves a pathogenic protein (my claims 1-4, especially my claim 4) and these my molecules comprise antioxidants (my claim 3) and these my molecules comprise phosphodiesterase inhibitor, thiol groups and sulphur as well as selenium (description, abstract and claim 3) and the molecules according to my invention cleave pathogenic proteins including beta-amyloids for treating Alzheimer's disesase, huntingtin in order to treat Huntington's Disesases and prions in order to treat prion diseases.
Thus your intellectual property can be reexamined and everybody can pay for that reexamination .
So why did you not referenced, not mentioned my basic invention DE19953696?
I ask you to do this, i.e. to mention my DE19953696.
On my person:
I was born 1981 in Zaporozhye, Ukraine, living since 1996 in Dusseldorf, Germany, have finished Goethe-Gymnasium and Heinrich-Heine-University in Dusseldorf, my inventions include causal therapeutic solutions for combating cancer, viruses (both in and outside of cells), autoimmune and immune complex diseases, inventions for rejuvenation and tissue regeneration, inventions of novel multi-parallel diagnostic and gene sequencing systems, new materials and high-quality synthetic diamonds, and I have German patents and published American, international and German patent applications claiming priority and novelty worldwide.
Known media including Stern (The Star) and Laborjournal (from November 2016, pages 54-58, this the link http://www.laborjournal.d
My patent documents were referenced in more than 27 patents of companies, universities and research institutes in 10 countries, in The USA, Canada, Spain, France, UK, Japan, China, Switzerland, Belgium and Germany.
The following is the partial list of these references:
1) My published patent document WO2006/136892 was referenced in the patent documents EP2447277 and WO2012055985 (for anti-HIV vaccines) of the Spanish company Laboratorios del Dr. Esteve and the research organization Fundacio Privada Institut de Reserca de la SIDA-Caixa
2) My patent DE19937512 was mentioned in the US Patent US7163658 (for sequencing of nucleic acid sequences) of the American inventor Rouvain Bension
3) DE19937512 mentioned in the US Patent US8153438 of Halcyon Molecular
4) DE19953696 mentioned in the US Patent US7557182 of the Canadian firm Angiochem
5) DE19953696 mentioned in the US Patent US7902156 of Angiochem
6) DE19953696 mentioned in the US Patent US8710013 of Angiochem
7) DE19953696 mentioned in the US Patent US8828925 of Angiochem
8) DE19953696 mentioned in the US Patent US8828949 of Angiochem
9) DE19953696 mentioned in the US Patent US8853353 of Angiochem
10) DE19953696 mentioned in the US Patent US8921314 of Angiochem
11) DE19953696 mentioned in the US Patent US8969310 of Angiochem
12) DE19953696 mentioned in the US Patent US9161988 of Angiochem
13) DE19953696 mentioned in the US Patent US9173891 of Angiochem
14) DE19953696 mentioned in the US Patent US9365634 of Angiochem
15) DE19953696 mentioned in the US Patent US9221867 of Angiochem
16) DE19822406 mentioned in the US Patent US8034766 of the American company E I du Pont de Nemours and Company and University College London
17) DE19822406 mentioned in the US Patent US8431526 of E I du Pont de Nemours and Company
18) DE19925052 mentioned in the US Patent US7999073 of the Swiss company Lonza
19) DE19925052 mentioned in the US Patent US7320859 of the German firm Amaxa sold to Lonza
20) DE19925052 mentioned in the US Patent US9260471 of the American company Sirna
21) DE19925052 mentioned in the US Patent US9181551 of Sirna Therapeutics
22) DE19925052 mentioned in the US Patent US9657294 of Sirna Therapeutics
23) US20080242565 mentioned in the US Patent US8273694 von Americans Jeffrey Brown, Joseph Duimstra and Jason Wells
24) DE10160248 (especially for the Fc-AChR fusion proteins against the autoimmune disease Myasthenia gravis) was mentioned in the US Patent US9243071 of the Japanese company Nihon Pharmaceutical (Tokyo, JP)
25) DE10162870 mentioned in the US Patent US8679500 of the Institute National de la Sante et de la Recherche Medicale (INSERM) (Paris, FR), Universite de Bretagne Occidentale (Brest, FR) and Centre National de la Recherche Scientifique (CNRS) (Paris, FR)
26) DE10162867 mentioned in the US Patent US8772254 of Devgen N.V. in Belgium
27) DE102007027596 mentioned in the Chinese Patent CN102718882 of the University Nanjing Agricultural
The search can be made for example in the patent literature data bank of the United States Patent and Trademark Office http://patft.uspto.gov/
I ask you to respond within five days from this email, because I plan to make the according blog and further publicity based on the facts described above.
Sincerely,
Alexander Cherkasky
Dipl.-Biol. (M.Sc.) Alexander Cherkasky
Prinz-Georg-Str. 5
40477 Duesseldorf
Tel: +49 211 482179
Email: alexcherkasky@googlemai
Kommentare
Kommentar veröffentlichen